The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma (msn.com)
- Forums
- ASX - By Stock
- ALA
- FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
ALA
arovella therapeutics limited
Add to My Watchlist
0.00%
!
9.5¢

FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $113.6M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1023 | 9.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.5¢ | 1011 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1012 | 0.097 |
1 | 31578 | 0.095 |
1 | 15825 | 0.090 |
2 | 225000 | 0.089 |
3 | 125106 | 0.088 |
Price($) | Vol. | No. |
---|---|---|
0.095 | 424 | 1 |
0.096 | 587 | 1 |
0.097 | 100000 | 1 |
0.098 | 250000 | 1 |
0.099 | 359000 | 4 |
Last trade - 09.53am 17/09/2025 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |